Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Minority patients are underrepresented in hematology clinical trials, but this is improved by using nontraditional trial sites in other counties.
Andrew Schorr and Brian Koffman have been friends for almost two decades and both live with CLL. In a podcast episode, they recount their journey.
A clinical trial for those living with CLL and SLL is a carefully controlled research study to improve the overall care and treatment.
Both progression free survival (PFS) and measurable (minimal) residual disease (MRD) status were found to strongly correlate with overall survival (OS), suggesting these markers could be safely used as surrogates for OS and thus provide quicker results in clinical trials.
CLL Society applauds the FDA for approaching this long standing problem with flexibility that allows patients access to potentially lifesaving medications sooner, while still requiring drugs be appropriately studied in all populations that might benefit.
Overall response rate (ORR) is a robust surrogate marker for progression-free survival (PFS), especially when chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) is treated with a Bruton tyrosine kinase inhibitor (BTKi) such as ibrutinib, acalabrutinib or zanubrutinib, but is not well correlated with overall survival (OS).
This is the largest meta-analysis of AEs reported with covalent BTKIs. The results help us better understand the side effects of BTKIs in CLL
Considering a clinical trial may seem like a daunting prospect, but sometimes it can be the smartest strategy. Here are some basic questions to help you make a good decision. 1.
Ask the Doctor Question: How does the new BTKi Loxo-305 compare so far in clinical trials vs. the present approved BTKis in terms of side effects? Answer: We covered the oral presentation
One click to our most popular content.
